Tracy Basso - 21 Jul 2026 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: EVP & CHRO
Issuer ticker: N/A
Reported as of: 21 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 17:05:52 UTC
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Tracy Basso filed Form 4 for Keenova Therapeutics plc on 23 Jul 2026.

Key facts

This page summarizes Tracy Basso's Form 4 filing for Keenova Therapeutics plc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jul 2026, 17:05.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076534 Primary reporting owner

Basso Tracy

Relationship: EVP & CHRO
Address: 675 MCDONNELL BLVD., HAZELWOOD
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 23 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Ordinary Shares

Tax liability

Transaction value
Shares: -763
Change %: -33%
Price
Shares after: 1,542
Date: 21 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of restricted stock units ("RSUs"), which vested on April 23, 2026, is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.